Subcutaneous administration of anti-hepatitis B antibodies
The present application relates to an immunoglobulin preparation comprising anti-hepatitis B antibodies for subcutaneous administration and to uses thereof, including methods for treating, preventing and/or reducing a disease, disorder or condition associated with hepatitis B virus.
1. A method for subcutaneous immunoglobulin hepatitis B therapy, comprising subcutaneously administering to a subject in need a dose of anti-hepatitis B immunoglobulin that is at least 2-fold higher than a dose of anti-hepatitis B immunoglobulin administered by the intramuscular route, thereby achieving anti-hepatitis B antibodies in the circulation at a similar level and timing as by the intramuscular route, wherein said subcutaneous dose is higher than 2170 IU and the administration of the immunoglobulin is carried out in the body in an anatomic site selected from the group consisting of the arm, the abdomen, and the front of the thigh.
2. The method according to claim 1 , wherein said subject is selected from the group consisting of an orthotopic liver transplantation (OLT) patient, a newborn to a hepatitis B virus infected mother, and a subject exposed to the virus.
3. The method according to claim 1 , wherein said subcutaneous dose is equal to or higher than 3000 IU.
4. The method according to claim 1 , wherein said subcutaneous administering is carried out by injection.
5. The method according to claim 1 , wherein said subcutaneous administering is carried out by a single dispensation.
6. The method according to claim 1 , wherein said subcutaneous dose has a titer of anti-hepatitis B antibodies that is greater than 635 IU/ml.
7. A method for treating hepatitis B virus infection, comprising administering to a subject in need thereof a dose of anti-hepatitis B immunoglobulin sufficient to obtain a predetermined level of anti-hepatitis B antibodies in the circulation of said subject, the improvement wherein the anti-hepatitis B immunoglobulin is administered by the subcutaneous route in a dose that is at least 1.5 times higher than the intramuscular formulated dose needed to obtain said predetermined level of anti-hepatitis B antibodies in the circulation of said subject, wherein said predetermined level is obtained in the circulation by the subcutaneous dose at a similar timing as in said intramuscular formulated dose and wherein said subcutaneous dose is higher than 2170 IU and the administration of the immunoglobulin is carried out in the body in an anatomic site selected from the group consisting of the arm, the abdomen, and the front of the thigh.
8. The method according to claim 7 , wherein said predetermined level of anti-hepatitis B antibodies in the circulation is greater than 100 mIU/ml.
9. The method according to claim 7 , wherein said timing is before the third, second or first day following subcutaneous administration.
10. The method according to claim 7 , wherein said subcutaneous administration is carried out by injection.
11. The method according to claim 7 , wherein said subcutaneous administration is carried out by a single dispensation.
12. The method according to claim 7 , wherein said subject was previously treated by a dosing regimen of intravenous administration of anti-hepatitis B immunoglobulin.
13. The method according to claim 7 , wherein said subcutaneous dose has a titer of anti-hepatitis B antibodies that is greater than 635 IU/ml.
14. A method for preventing hepatitis B viral infection recurrence in a subject who underwent orthotopic liver transplantation (OLT), comprising administering to said subject a dose of anti-hepatitis B immunoglobulin sufficient to obtain a predetermined level of anti-hepatitis B antibodies in the circulation of said subject, the improvement wherein the anti-hepatitis B immunoglobulin is administered by the subcutaneous route in a dose that is at least 1.5 times higher than the intramuscular formulated dose needed to obtain a similar level of anti-hepatitis B antibodies in the circulation of said subject, wherein said predetermined level is obtained in the circulation by the subcutaneous dose at a similar timing as in said intramuscular formulated dose and wherein said subcutaneous dose is higher than 2170 IU and the administration of the immunoglobulin is carried out in the body in an anatomic site selected from the group consisting of the arm, the abdomen, and the front of the thigh.
15. The method according to claim 14 , wherein said subcutaneous administering is carried out by injection.
16. The method according to claim 14 , wherein said subcutaneous administering is carried out by a single dispensation.